Author

P. Sonneveld

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Assay:flow cytometry· 2 Assay:scRNA-seq· 2 Approach:benchmark study· 1

Frequent Co-Authors

A. Broijl· 3 shared C. Fokkema· 3 shared N. Papazian· 3 shared R. Hoogenboezem· 3 shared S. Tahri· 3 shared T. Cupedo· 3 shared F. Gay· 2 shared G. Van Beek· 2 shared

Activity by Year

2019-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. Broijl

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Single-cell transcriptomic analysis of NK cell dynamics in myeloma patients reveal persistent reduction of cytotoxic NK cells from diagnosis to relapse

S. Tahri, M. M. E. de Jong, C. Fokkema, N. Papazian, Z. Kellermayer, M. Vermeulen, M. Van Duin, G. Van Beek, R. Hoogenboezem, P. Van De Woestijne, K. Nasserinejad, E. Saraci, M. D'Agostino, F. Gay, V. Van Der Velden, , T. Cupedo

bioRxiv · Jul 5, 2023 · PreprintImmunology

An IL-1β driven neutrophil-stromal cell axis fosters a BAFF-rich microenvironment in multiple myeloma

M. M. de Jong, C. Fokkema, N. Papazian, T. van Heusden, M. Vermeulen, R. Hoogenboezem, G. van Beek, S. Tahri, M. A. Sanders, P. van de Woestijne, F. Gay, P. Moreau, M. Büttner-Herold, H. Bruns, M. van Duin, , T. Cupedo

The paper identifies a neutrophil-stromal cell feedback loop in multiple myeloma that promotes BAFF-rich inflammation, persisting after treatment and suggesting dual targeting strategies.

bioRxiv · Mar 3, 2023 · PreprintImmunology

Immune-mediated tumor control in the 5TGM1 transfer model of multiple myeloma

Z. Kellermayer, S. Tahri, M. M. E. De Jong, N. Papazian, C. Fokkema, R. Hoogenboezem, M. A. Sanders, L. Boon, C. Den Hollander, A. Broijl, P. Sonneveld, T. Cupedo

This study uses a murine model to show that C57Bl/6 mice can control multiple myeloma through IFN-gamma-dependent immune responses, highlighting the model's utility for studying anti-myeloma immunity.

bioRxiv · Jan 18, 2023 · PreprintImmunology

Multiple Myeloma DREAM Challenge Reveals Epigenetic Regulator PHF19 As Marker of Aggressive Disease

M. J. Mason, C. Schinke, C. Eng, F. Towfic, F. Gruber, A. Dervan, B. S. White, A. Pratapa, Y. Guan, H. Chen, Y. Cui, B. Li, T. Yu, E. Chaibub Neto, K. Mavrommatis, , J. A. Guinney

The paper identifies PHF19 as a marker of aggressive multiple myeloma and shows a simple four-feature model performs as well as complex gene expression models.

bioRxiv · Aug 22, 2019Cancer Biology